Hjem › Burkitts lymfom
Kliniske studier for Burkitts lymfom rekrutterer i USA
63 studier for Burkitts lymfom rekrutterer deltakere på steder over hele USA.
Byer med flest studier
- Houston, TX21 studier
- Milwaukee, WI16 studier
- Philadelphia, PA16 studier
- New York City, NY14 studier
- Chicago, IL14 studier
- Cincinnati, OH12 studier
- Atlanta, GA12 studier
- Seattle, WA11 studier
- Boston, MA10 studier
- Durham, NC10 studier
- Kansas City, MO10 studier
- Los Angeles, CA10 studier
- Aurora, CO10 studier
- Orange, CA9 studier
- Minneapolis, MN9 studier
- Washington, DC9 studier
- Baldwin Park, CA9 studier
- Buffalo, NY8 studier
- Columbus, OH8 studier
- Portland, OR8 studier
- Baltimore, MD8 studier
- San Francisco, CA8 studier
- Nashville, TN8 studier
- Ann Arbor, MI8 studier
- Tampa, FL7 studier
- Dallas, TX7 studier
- Clifton, NJ7 studier
- Providence, RI7 studier
- Jacksonville, FL7 studier
- Greenburgh, NY7 studier
- Birmingham, AL7 studier
- Richmond, VA7 studier
- Cleveland, OH7 studier
- San Antonio, TX7 studier
- Grand Rapids, MI7 studier
- Salt Lake City, UT7 studier
- Oklahoma City, OK7 studier
- The Bronx, NY6 studier
- Mountain View, CA6 studier
- Cicero, IL6 studier
Etter delstat
- Alabama7 studier
- Arizona7 studier
- Arkansas5 studier
- California20 studier
- Colorado13 studier
- Connecticut7 studier
- Delaware7 studier
- District of Columbia5 studier
- Florida15 studier
- Georgia12 studier
- Hawaii5 studier
- Idaho6 studier
- Illinois14 studier
- Indiana6 studier
- Iowa7 studier
- Kansas6 studier
- Kentucky5 studier
- Louisiana4 studier
- Maine4 studier
- Maryland11 studier
- Massachusetts10 studier
- Michigan10 studier
- Minnesota10 studier
- Mississippi4 studier
- Missouri8 studier
- Nebraska5 studier
- Nevada6 studier
- New Hampshire4 studier
- New Jersey8 studier
- New Mexico3 studier
- New York20 studier
- North Carolina13 studier
- North Dakota5 studier
- Ohio17 studier
- Oklahoma7 studier
- Oregon8 studier
- Pennsylvania18 studier
- Rhode Island7 studier
- South Carolina5 studier
- South Dakota5 studier
- Tennessee10 studier
- Texas24 studier
- Utah7 studier
- Vermont3 studier
- Virginia7 studier
- Washington11 studier
- West Virginia3 studier
- Wisconsin17 studier
Nylig oppdaterte studier
Offisiell studietekst (engelsk)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RekruttererFase 2
366 Days – 46 Years · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RekruttererFase 3
Alder 18 til 39 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT03150693Blinatumomab Consolidation in Real World
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07117136Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruttererObservasjonsstudie
Alder 0 til 38 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
RekruttererFase 1/2
Alder 3 til 39 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT05442515Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT03739814Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RekruttererFase 1/2
Alder 18 til 120 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT03223610Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06144606Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekruttererFase 2
365 Days · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
RekruttererFase 3
Alder 1 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RekruttererFase 1/2
6 Months – 25 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RekruttererFase 1
Alder 0 til 18 · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06173518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
RekruttererFase 1/2
31 Days – 30 Years · Alle kjønn · Oppdatert 14. sep. 2026 · NCT04544592Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RekruttererFase 2
Alder 1 til 30 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT04546399Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
RekruttererFase 1
Alder 18 til 120 · Alle kjønn · Oppdatert 25. aug. 2026 · NCT05389423Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekruttererFase 3
365 Days – 25 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT06710418Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RekruttererFase 2
Alder 7 til 25 · Alle kjønn · Oppdatert 19. aug. 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT06137118AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 12. aug. 2026 · NCT06340737Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 10. aug. 2026 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
RekruttererFase 2
Alder 15 og eldre · Alle kjønn · Oppdatert 10. aug. 2026 · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
Alder 13 til 90 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06533579Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.